The COVID-19 pandemic has raised questions about the approach to management of systemic immunosuppressive therapies for dermatologic indications in children. Given the absence of data to address concerns related to SARS-CoV-2 infection while on these agents in an evidence-based manner a Pediatric Dermatology COVID-19 Response Task Force PDCRTF was assembled to offer time-sensitive guidance for clinicians. Systemic Immunosuppressive\xa0Therapy for Inflammatory Skin Diseases in Children: Expert-Consensus-Based Guidance for Clinical Decision Making During the COVID-19 Pandemic.